The 2026 Sweden Life Science Trend Analysis, produced in partnership with Business Region Göteborg and Invest in Skåne, highlights one of Northern Europe’s leading life science ecosystems, anchored by two strong clusters: Gothenburg, home to Northern Europe’s largest university hospital and one of AstraZeneca’s three global strategic R&D centres, and Skåne, part of Medicon Valley and home to 27% of Sweden’s national drug pipeline.
The ecosystem encompasses 1,627 companies in total, including 452 biotech firms, 260 medtech companies, 120 digital health companies, 91 investor companies, and 37 fully integrated pharma companies. Within the biotech segment, R&D services (186 companies, 41%) and therapeutics & diagnostics (180 firms, 40%) are almost evenly balanced, while “other” biotech (agrobio, cosmetic, nutraceutical, etc.) makes up the remaining 86 (19%). The leading therapeutic activities are anti-infectives, immunotherapy and antibodies (9% each), followed by proteins (8%). Oncology leads the clinical pipeline with 186 assets, followed by neurology (71) and infectiology/parasitology (52). The pipeline is relatively mature, with 113 assets in Phase II and 26 in Phase III alongside 144 in preclinical and 83 in Phase I. A total of 648 assets are available for out-licensing, with 407 of those being therapeutics — the majority still preclinical (186) — and a notable 149 medical devices.
The ownership landscape is predominantly private and independent across most sectors (70–91% for medtech and digital health), while biotech therapeutics & diagnostics stands out with 29% publicly listed. Pharma is the clear exception at only 27% private versus 19% publicly listed and 54% subsidiary — reflecting the strong presence of multinational operations in the country. Company formation peaked between 2016 and 2018 (34–35 companies per year), with a visible contraction from 2021 and only 13 companies recorded in 2024, consistent with the broader global slowdown in life science incorporations.
Financing activity tells a split story: private equity rounds for life science companies rose from $491M in 2025 to $766M in 2026, driven by digital health, while biotech-specific funding fell from $180M to $66M. The five-year half-yearly biotech dataset peaks in 2022 H2 ($196.38M across 9 rounds), followed by a prolonged trough and a modest $46.91M in 2026 H1. Digital health dominated the top 2024–2026 rounds, led by Neko Health ($700M Series C and $260M Series B), NaturalCycles ($55M Series C) and Tandem Health ($50M Series A), with SmartCella ($53.9M) the largest biotech round. On the M&A front, the most notable deal was SERB’s acquisition of a division/asset from Hansa Biopharma ($131.2M), alongside Flerie’s acquisition of Toleranzia ($4.8M), Nosa Plugs’ acquisition of Pharmacure Health Care ($2.9M), and the undisclosed-value acquisitions of WntResearch by Opsy Holding and Entomed Medtech by Demant.
Looking ahead, Sweden’s life science sector is supported by world-class clinical and academic infrastructure, a strong medtech base and a maturing clinical pipeline — positioning it as a key Nordic hub, with digital health attracting record investment even as biotech financing works through a cyclical downturn.
For more detailed insights, request a free Biotechgate demo.
Download the Sweden Trend Analysis Report 2026 for the full PDF.